We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Lack of Autoantibodies Against Related Proteins in Collagenous Colitis

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Histological features of collagenous colitis (Photo courtesy of Michael Bonert, MD, FRCPC)
Image: Histological features of collagenous colitis (Photo courtesy of Michael Bonert, MD, FRCPC)

Collagenous colitis (CC) is an inflammatory disorder in the colonic mucosa that predominantly affects elderly women and causes chronic, non-bloody diarrhea with normal or close to normal endoscopic findings.

The histological criteria for CC are a thickened sub-epithelial collagen layer (> 10 µm) in the extracellular matrix (ECM) of the mucosa, epithelial damage and presence of an inflammatory infiltrate in the lamina propria. CC shares many of the characteristics found in autoimmune diseases, but no autoantibodies have been identified. In CC, an imbalance in collagen turnover is evident.

Gastroenterologists at the Skåne University Hospital (Malmö, Sweden) included in a study, 66 women with CC. The mean age at inclusion was 60 years (range 31–74 years) and mean age at diagnosis was 55 years (range 28–69 years). The size of the control groups differed, but they were selected from the same cohort consisting of 100 healthy female blood donors. The mean age of the total control group was 41.7 years (range 19–69).

In-house enzyme-linked immunosorbent assays (ELISAs) were set up for analysis of anti-IgM and IgG antibodies against collagen type III (Col III and IV). Analyses of antibodies against matrix metalloproteinase-9 (MMP-9 and Tenascin-C (TNC) were conducted by in-house ELISAs and another in-house ELISA was set up for analysis of IgM and IgG antibodies against tissue inhibitors of metalloproteinase (TIMP-1). Anti-Saccharomyces cerevisiae antibodies (ASCA) IgG were analyzed by a fluorescent enzyme immunoassay method (FEIA) for which the reference value is set > 10 U/mL (Orgentec Diagnostika, Mainz, Germany). Thyroid peroxidase (TPO) antibodies were analyzed by a chemiluminescence enzyme immunological method (Siemens Healthcare GmbH, Erlangen, Germany).

The investigators reported that there was no difference in prevalence of these collage-associated autoantibodies between CC patients and controls. Sixteen patients expressed one type of autoantibody, whereas two patients expressed two different types. The mean disease duration was significantly lower in the subjects who expressed collagen-associated autoantibodies (3.7 years; range 1–14), compared to those who did not (6.4 years; range 1–22). The presence of autoantibodies against TPO and ASCA was slightly increased compared to controls, but not statistically significant. Increased levels of total IgE were equally present in the CC patients and the control group, and there was no correlation between total IgE-positivity and presence of any autoantibodies.

The authors concluded that no increased presence of the investigated antibodies could be found in the present study of CC. Neither could antibodies against ASCA or TPO, or elevated levels of IgE, be found. Consequently, no association was found between CC and these proteins, even though this may not be generalizable to other compounds in the collagen layer. The study was published on June 6, 2022 in the journal BMC Immunology.

Related Links:
Skåne University Hospital 
Orgentec Diagnostika 
Siemens Healthcare GmbH 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.